Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Net Margin (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Net Margin for 7 consecutive years, with 18.2% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 3930.0% to 18.2% in Q4 2025 year-over-year; TTM through Dec 2025 was 29.74%, a 22890.0% increase, with the full-year FY2025 number at 29.74%, up 22890.0% from a year prior.
  • Net Margin was 18.2% for Q4 2025 at Madrigal Pharmaceuticals, up from 38.68% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 18.2% in Q4 2025 to a low of 1038.2% in Q2 2024.